ClinicalTrials.gg

Program

MHB018A

A development code. Also written as “MHB018A injection”.

Its studies are mostly in Graves Ophthalmopathy, led by Minghui Pharmaceutical.

Furthest: phase 3, since May 9, 20256 company-led studies, 6 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Minghui Pharmaceutical66 open or runningphase 3since May 9, 2025May 9, 2025Dec 2026phase 3 · NCT06989918

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 9, 2025First study: phase 3 study in Graves OphthalmopathyFirst studyNCT06989918 · 108 enrolled · China
  2. Nov 20, 20252 phase 3 studies in Graves OphthalmopathyNCT07262476, NCT07257185
  3. May 27, 20263 phase 3 studies in Graves OphthalmopathyNCT07622121, NCT07622108, NCT07620405
  4. Oct 9, 2026Primary completion moved from 2026-07-31 to 2026-12Date moved laterphase 3 · +5 months · NCT06989918

Ahead

  1. Dec 2026Primary completion: phase 3 study in Graves OphthalmopathyNCT06989918
  2. Aug 31, 2027Primary completion: phase 3 study in Graves OphthalmopathyNCT07257185
  3. Jul 2028Primary completion: phase 3 study in Graves OphthalmopathyNCT07622121
  4. Jul 2028Primary completion: phase 3 study in Graves OphthalmopathyNCT07622108

TargetBeta

IGF1R →read by rule
“The investigational drug, MHB018A, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R).”study text, by rule · the study

Other programs on IGF1R

ProgramCompanyFurthest phaseStudies
teprotumumabruleAmgenphase 418
veligrotugruleviridian-therapeutics-incphase 47
linsitinibruleAstellas Pharmaphase 313
IBI311ruleInnovent Biologicsphase 35
IBI3031ruleInnovent Biologicsphase 11

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07622121Graves Ophthalmopathy · United States3RecruitingJul 2028135
NCT07622108Graves Ophthalmopathy · United States3RecruitingJul 202884
NCT07620405Graves Ophthalmopathy3Not yet recruitingJan 2030219
NCT07262476Graves Ophthalmopathy · China3RecruitingJan 31, 2029258
NCT07257185Graves Ophthalmopathy · China3Active, not recruitingAug 31, 2027150
NCT06989918Graves Ophthalmopathy · China3Active, not recruitingDec 2026108

How it is read

Names in the registry

  • “MHB018A injection”, 4 entries
  • “MHB018A”, 2 entries

Codes read as this program: MHB018A.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.